FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069650596> ?p ?o ?g. }

• W2069650596 endingPage "S41" @default.
• W2069650596 startingPage "S31" @default.
• W2069650596 abstract "Treatment of chronic hepatitis C virus (HCV) infection has substantially evolved over the past decade after the Consensus Conference organized by the European Association for the Study of the Liver in 1999. Since then, the standard of care (SOC) for patients with chronic hepatitis C has been the combination of pegylated interferon (pegIFN) alpha-2a or -2b and ribavirin. In patients infected with HCV genotype 1, by far the most frequent HCV genotype worldwide, such treatment leads to a cure of infection in only 40% to 50% of cases. Several factors have been identified to play a role in the outcome of therapy, including the treatment schedule, disease characteristics, viral, and host factors. Human genetic factors have been identified by a recent landmark discovery. However, these factors only partly explain the ability of IFN and ribavirin therapy to cure HCV infection. Several studies have demonstrated that, in non-responders, interferon-stimulated genes were up-regulated prior to therapy through unclear mechanisms. These findings, together with clinical, biochemical and histological data, may help better identify responders before starting therapy. This becomes particularly important as the standard treatment is physically and economically demanding. The future treatment of patients infected with HCV genotype 1 will be based on the combination of pegIFN and ribavirin with a protease inhibitor, telaprevir or boceprevir. Promising results of this triple combination in phase III clinical trials have been recently reported at the Liver Meeting 2010. With this therapy, higher cure rates will be achieved, but specific issues will be raised, such as the emergence of resistance to the protease inhibitors. The goal of this review is to discuss mechanisms involved in the non-response to current and future standard treatments.Key points•Viral genotype should be assessed before the start of antiviral treatment by means of a molecular method allowing an accurate determination between subtype 1a from 1b.•HCV RNA levels should be performed regularly but the ideal times points, frequency need to be further evaluated in the context of protease inhibitor-based therapies.•Resistant variants to DAAs preexist in virtually all HCV infected patients who had never been exposed to drugs before.•Genotypic resistance testing at baseline is not recommended in clinical practice.•Accurate methods to assess HCV treatment adherence remain to develop.•In order to prevent HCV resistance, combination of DAAs with at least additive effects and no cross-resistance should be used. Key points Viral genotype should be assessed before the start of antiviral treatment by means of a molecular method allowing an accurate determination between subtype 1a from 1b. HCV RNA levels should be performed regularly but the ideal times points, frequency need to be further evaluated in the context of protease inhibitor-based therapies. Resistant variants to DAAs preexist in virtually all HCV infected patients who had never been exposed to drugs before. Genotypic resistance testing at baseline is not recommended in clinical practice. Accurate methods to assess HCV treatment adherence remain to develop. In order to prevent HCV resistance, combination of DAAs with at least additive effects and no cross-resistance should be used." @default.
• W2069650596 created "2016-06-24" @default.
• W2069650596 creator A5009032052 @default.
• W2069650596 creator A5071079774 @default.
• W2069650596 date "2011-06-01" @default.
• W2069650596 modified "2023-10-01" @default.
• W2069650596 title "Mechanisms of non-response to antiviral treatment in chronic hepatitis C" @default.
• W2069650596 cites W1497131577 @default.
• W2069650596 cites W1583671795 @default.
• W2069650596 cites W1669433281 @default.
• W2069650596 cites W1831899697 @default.
• W2069650596 cites W1907925115 @default.
• W2069650596 cites W1964494489 @default.
• W2069650596 cites W1968502220 @default.
• W2069650596 cites W1970734373 @default.
• W2069650596 cites W1974655579 @default.
• W2069650596 cites W1974922859 @default.
• W2069650596 cites W1976678178 @default.
• W2069650596 cites W1978088727 @default.
• W2069650596 cites W1979174109 @default.
• W2069650596 cites W1980233888 @default.
• W2069650596 cites W1982433898 @default.
• W2069650596 cites W1983364530 @default.
• W2069650596 cites W1985241178 @default.
• W2069650596 cites W1987749699 @default.
• W2069650596 cites W1989022528 @default.
• W2069650596 cites W1993262285 @default.
• W2069650596 cites W1995565071 @default.
• W2069650596 cites W1997514631 @default.
• W2069650596 cites W2000336618 @default.
• W2069650596 cites W2001128050 @default.
• W2069650596 cites W2017013905 @default.
• W2069650596 cites W2019312361 @default.
• W2069650596 cites W2020939898 @default.
• W2069650596 cites W2021143480 @default.
• W2069650596 cites W2023309777 @default.
• W2069650596 cites W2023481708 @default.
• W2069650596 cites W2026614040 @default.
• W2069650596 cites W2027252289 @default.
• W2069650596 cites W2027480021 @default.
• W2069650596 cites W2027545702 @default.
• W2069650596 cites W2030893956 @default.
• W2069650596 cites W2034182580 @default.
• W2069650596 cites W2037332452 @default.
• W2069650596 cites W2040277070 @default.
• W2069650596 cites W2041186969 @default.
• W2069650596 cites W2042728642 @default.
• W2069650596 cites W2043519223 @default.
• W2069650596 cites W2044102082 @default.
• W2069650596 cites W2044276375 @default.
• W2069650596 cites W2045877860 @default.
• W2069650596 cites W2054586386 @default.
• W2069650596 cites W2058538904 @default.
• W2069650596 cites W2059821506 @default.
• W2069650596 cites W2061445408 @default.
• W2069650596 cites W2062749605 @default.
• W2069650596 cites W2063285149 @default.
• W2069650596 cites W2063859957 @default.
• W2069650596 cites W2064546869 @default.
• W2069650596 cites W2073758827 @default.
• W2069650596 cites W2077159378 @default.
• W2069650596 cites W2085907274 @default.
• W2069650596 cites W2086414517 @default.
• W2069650596 cites W2086795705 @default.
• W2069650596 cites W2087793753 @default.
• W2069650596 cites W2095010714 @default.
• W2069650596 cites W2098887521 @default.
• W2069650596 cites W2100584373 @default.
• W2069650596 cites W2100797437 @default.
• W2069650596 cites W2101682111 @default.
• W2069650596 cites W2105599476 @default.
• W2069650596 cites W2107020066 @default.
• W2069650596 cites W2112876622 @default.
• W2069650596 cites W2118047427 @default.
• W2069650596 cites W2118542945 @default.
• W2069650596 cites W2119661624 @default.
• W2069650596 cites W2119764771 @default.
• W2069650596 cites W2127685726 @default.
• W2069650596 cites W2132116288 @default.
• W2069650596 cites W2159176940 @default.
• W2069650596 cites W2159835094 @default.
• W2069650596 cites W2160304230 @default.
• W2069650596 cites W2164301466 @default.
• W2069650596 cites W2171945301 @default.
• W2069650596 cites W2317554121 @default.
• W2069650596 cites W2740336755 @default.
• W2069650596 cites W98584085 @default.
• W2069650596 doi "https://doi.org/10.1016/s2210-7401(11)70005-5" @default.
• W2069650596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21742299" @default.
• W2069650596 hasPublicationYear "2011" @default.
• W2069650596 type Work @default.
• W2069650596 sameAs 2069650596 @default.
• W2069650596 citedByCount "20" @default.
• W2069650596 countsByYear W20696505962012 @default.
• W2069650596 countsByYear W20696505962013 @default.
• W2069650596 countsByYear W20696505962014 @default.
• W2069650596 countsByYear W20696505962015 @default.
• W2069650596 countsByYear W20696505962018 @default.

• next